Literature DB >> 30593685

Comparison of contemporary staging systems for oropharynx cancer in a surgically treated multi-institutional cohort.

Olgun Elicin1, Martina A Broglie2,3, Niklaus Fankhauser4, Sandro J Stoeckli2, Philippe Pasche5, Antoine Reinhard5, Massimo Bongiovanni6, Gerhard F Huber2,3, Grégoire B Morand3, Alex Soltermann7, Andreas Arnold8, Matthias S Dettmer9, André Arnoux10, Edouard Stauffer11, Vittoria Espeli12, Francesco Martucci13, Daniel M Aebersold1, Roland Giger8.   

Abstract

BACKGROUND: Between the publication of the Union of International Cancer Control staging system (UICC) 7th and 8th editions, other staging algorithms for oropharyngeal squamous cell carcinoma (OPSCC) were proposed from Radiation Therapy Oncology Group (RTOG), MD Anderson Cancer Center (MDACC), and Yale University.
METHODS: With C-statistics, the above-mentioned five staging algorithms were compared for overall and relapse-free survival endpoints in a multi-institutional cohort of OPSCC cases (n = 338) treated with primary surgery.
RESULTS: Pathological UICC 8th ed yielded the highest C-indexes in the entire cohort and in the HPV- subset, whereas MDACC was superior for HPV+ OPSCC. RTOG was the simplest and holistic algorithm with a noninferior discriminatory power.
CONCLUSION: UICC 8th ed, MDACC, and RTOG offer moderate and comparable efficacy for staging in this OPSCC patient cohort undergoing surgical treatment. Notable discrepancy between clinical and pathological UICC 8th ed algorithms poses potential concerns in diagnosis, treatment, research, and data management.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer staging; head and neck cancer; human papillomavirus; oropharynx cancer; surgery

Year:  2018        PMID: 30593685     DOI: 10.1002/hed.25574

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

Review 1.  HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.

Authors:  Matt Lechner; Jacklyn Liu; Liam Masterson; Tim R Fenton
Journal:  Nat Rev Clin Oncol       Date:  2022-02-01       Impact factor: 65.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.